MedPath

BREMISS : Brain Resilience Minor Stroke Study

Not Applicable
Not yet recruiting
Conditions
Stroke Ischemic
Registration Number
NCT06995040
Lead Sponsor
University Hospital, Brest
Brief Summary

All patients eligible recorded in the Brest Stroke Registry (BSR) will be proposed to have either a telephone interview or a face-to-face interview.

In the case of telephone interview, they will be proposed to have a saliva kit for DNA analysis send to their home at the time as the self-questionnaires that will need to be send back to the hospital.

In the case of face-to-face interview, they will be proposed to have on the spot a saliva sample for DNA and a cerebral MRI.

Around 1000 patients can be included.

Detailed Description

The study is a retrospective study for pairing the population-based stroke registry and hospital medical record data and prospective study for calling back patient more than 4 years for new clinical, cognitive, thymic and quality of life evaluations and for DNA sample and cerebral MRI realization Duration of recruitment is anticipated to last between 2 years and 2 years and half.

The principal objective is to develop a predictive model of quality of life more than 4 years after stroke onset in patients with minor stroke based on initial (first days after stroke onset) patients characteristics based on the assumption that more than 4 years after a stroke the related sequelae are going to be stable.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
1000
Inclusion Criteria
  • Cases of stroke in the Brest Stroke Registry (BSR)
  • Ability to sign informed consent
  • Patients followed-up > 4 years during the study period
  • NIHSS score ≤ 5 on admission
  • First stroke above 18 and before 75-year old
  • Rankin before stroke < 1
  • Possibility to draw saliva samples for genomic study
  • Possibility to perform Cerebral MRI
Exclusion Criteria
  • Patients with transient neurological deficits resolving within one hour and normal brain imaging will be excluded.
  • Not affiliated to social security
  • Patient under legal protection or deprived of liberty by a judicial or administrative decision
  • Patient unable to sign informed consent
  • Patient whose follow-up will be impossible

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Quality of life scoreAt inclusion

Quality of life score is evaluated with the SF-36 questionnaire. It is a dichotomized score : good or bad recovery

Secondary Outcome Measures
NameTimeMethod
Center for Epidemiologic Studies-Depression (CES-D)At inclusion

It is an auto-questionnaire to evaluate depression with 20 questions. There are 6 answers with score ranging from 0 to 6 (0 : Never/very rarely ; 1: rarely; 2 :quite often; 3: frequently/always).

Generalized Anxiety Disorder-7 (GAD-7)At inclusion

It is an auto-questionnaire for screening of generalized anxiety disorder with 7 questions. There are 4 answers : Never / Several days / More than half the days / Almost every day.

Primary Care PTSD Screen for DSM-5 (PTSD-5)At inclusion

It is an auto-questionnaire to evaluate stroke experience. there are 5 questions with 2 answers Yes/No

APATHY INVENTORY IAAt inclusion

It is an auto-questionnaire to obtain information on the presence of apathy in patients with brain disorders. There are 3 items : emotional blunting; loss of initiative; loss of interest, with score ranging from 0 (mild) to 12 (severe).

Multidimensional Fatigue Inventory (MFI)At inclusion

It is an auto-questionnaire to evaluate fatigue. There are 10 items with score ranging from 1 (not agree at all) to 5 (completely agree)

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)At inclusion

It is a questionnaire to evaluate cognitive declin, with 16 questions, with score ranging from 1 (much better) to 5 (much worse)

Clinical Functioning Information Tool (ClinFIT)At inclusion

It is an auto-questionnaire to evaluate patient functioning. There are 30 questions, with score ranging from 0 (no problem) to 30 (complete problem).

Montreal Cognitive Assesment (MoCA)At inclusion

It is a cognition test with 7 items (visuospatial; designation; memory; attention; langage; abstraction; orientation). The total score is ranging from 0 to 30 points.

Mini Mental State Examination (MMSE)At inclusion

It is a cognition test with 6 items (orientation ; learning ; attention/calculation ; reminder; langage ; visuospatial constructive). The total score is ranging from 0 to 30 points.

EQ5D scoreAt inclusion

It is a questionnaire to describe patient's health with 5 items (Mobility; Autonomy; Activity; Pain/Discomfort; Anxiety/Depression) with 5 anwers each (No problem/light problems/moderate problem/serious problems/incapable)

Stroke Impact ScaleAt inclusion

Stroke Impact Scale includes 59 items and assesses 8 domains: Strength (4 items), Hand function (5 items), ADL/IADL (10 items), Mobility (9 items), Communication (7 items), Emotion (9 items), Memory and thinking (7 items), Participation/Role function (8 items)

MortalityAt inclusion

Mortality is collected from the Brest Stroke Registry, and concerns patients who have been stroke 4 years ago.

RecurrenceAt inclusion

Recurrence is collected from the Brest Stroke Registry, and concerns patients who have been stroke 4 years ago.

Rankin scoreAt inclusion

It is a scale about disability after stroke. The score is between 0 (no symptom) to 5 (serious disability). The study uses Rankin score dichotomized in good \[0-1\] and bad \[2-5\] prognosis.

Utility-Weighted Modified Rankin ScaleAt inclusion

The Modified Rankin Scale is a measure of functional outcome after stroke, evaluating the degree of disability or dependence in daily life. There is 7 grades ranging from 0 (no symptoms) to 6 (death).

WHO Disability Assessment Schedule (WHODAS)At inclusion

It is an auto-questionnaire of disability in daily life. There are 15 questions with 5 anwers ranging from 0 (No disability) to 5 (extreme disability/incapability)

Trial Locations

Locations (1)

CHU de Brest

🇫🇷

Brest, France

CHU de Brest
🇫🇷Brest, France
Serge TIMSIT, Pr
Principal Investigator
© Copyright 2025. All Rights Reserved by MedPath